BCA
EGRX

Berman Capital Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Berman Capital Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Hold
35
– – ﹤0.01% 2008
2021
Q2 		$1K Buy
35
+3
+9% +$124 ﹤0.01% 1841
2021
Q1 		$1K Hold
32
– – ﹤0.01% 1720
2020
Q4 		$1K Hold
32
– – ﹤0.01% 1614
2020
Q3 		$1K Buy
+32
New +$1.4K ﹤0.01% 1544

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Berman Capital Advisors's EGRX Position: Q3 2021 in Review

Berman Capital Advisors held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q3 2021 at 35 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2008.

Berman Capital Advisors first reported a position in EGRX in Q3 2020 and has held it in 5 quarters since. 151 funds tracked by Wall St. Rank hold EGRX as of Q3 2021.

  • Berman Capital Advisors held 35 shares of Eagle Pharmaceuticals, Inc. worth $1K as of Q3 2021.
  • Berman Capital Advisors left its Eagle Pharmaceuticals, Inc. share count unchanged in Q3 2021.
  • Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2008 holding.
  • Berman Capital Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2020 and has held it in 5 quarters since.
  • 151 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.